Rokote Laboratories Finland Oy


Rokote is a Finnish biotech company currently developing an intranasal COVID-19 vaccine. Our IMP manufacturing has started, and we are planning to start the phase I clinical trial with ca. 100 subjects at the beginning of 2024. We have good understanding of nasal physiology and the challenges of mucosal vaccine administration, hence together with our highly immunogenic adenovirus vector vaccine platform we are confident to overcome the traditional intranasal administration hurdles. The same vaccine technology can also enable the rapid development of new vaccines against other viruses in various diseases.
We are looking for partnerships.